1. Key Guidance Documents
The main focus is on two new draft guidances that outline the FDA’s current thinking on manufacturing and quality control [02:29]:
- Manufacturing Changes and Comparability: For Human Cellular and Gene Therapy Products.
- Potency Assurance: For Cellular and Gene Therapy Products.
In addition to these, the FDA plans to release several more guidances in 2024 covering safety testing, donor eligibility, and FAQs to provide further clarity [08:18].
2. Core Concepts for Comparability
When making a change to the manufacturing process, the FDA emphasizes a formal, risk-based approach [11:30].
- Plan Ahead: Manufacturers are advised to anticipate future changes, retain samples from different manufacturing stages, and have a clear understanding of their analytical assays [13:22].
- Phase-Appropriate Data: The level of evidence needed to prove comparability increases as a product moves through clinical development. More rigor is expected for late-stage products compared to early-phase ones [14:50].
- Definitive Conclusion Required: A comparability study must provide a clear conclusion. An “inconclusive” result is considered a failure to demonstrate comparability [18:52].
- Consult the FDA: Sponsors are encouraged to proactively discuss significant manufacturing changes with the FDA and involve statisticians early in the planning process [16:26].
3. Core Concepts for Potency Assurance
The FDA is shifting from a focus on a single potency assay to a broader “Potency Assurance Strategy” [22:35].
- Holistic Approach: Potency is not just about the final release test. It must be built into the entire manufacturing process, including material controls, process parameters, and in-process testing [26:07].
- Identify Critical Attributes: Manufacturers must identify the specific Critical Quality Attributes (CQAs) that relate to the product’s potency [24:01].
- Multiple Assays Needed: A comprehensive potency strategy typically requires multiple release assays, including at least one bioassay that measures the product’s biological function [26:42].
- Lifecycle Implementation: The potency strategy should be developed and refined throughout the product’s lifecycle, from early development to post-approval [28:40].
4. CMC Development and Readiness Pilot (CDRP)
The FDA highlighted a pilot program (CDRP) running through 2027 designed to help accelerate development for products with expedited designations like RMAT or Breakthrough [31:23]. This program provides sponsors with additional, CMC-focused meetings to get early and more frequent advice from the agency, facilitating a smoother path toward approval [32:00].
